Inhaled anti-infective agents: emphasis on colistin.

摘要: The administration of antibiotics by the inhaled route is a widely recognized treatment in patients with cystic fibrosis (CF) and bronchiectasis. Tobramycin solution for inhalation (TOBI) has been available many years licensed USA Europe. While strong data support use aerosolized respiratory infections CF or bronchiectasis, only few clinical studies have examined role pneumonia, including ventilator-associated pneumonia (VAP) these patients. During last decade increasing interest directed towards alternative treatments to systemic antimicrobial agents hospital-acquired VAP due multidrug-resistant (MDR) Gram-negative bacteria. Recent publications demonstrate benefits from administering aminoglycosides polymyxins hospitalacquired VAP. In addition antibiotics, antifungals, antivirals administered specific groups critically ill However, randomized controlled trials dealing anti-infective via tract are necessary order validate efficacy, safety, advantages, disadvantages this therapeutic approach nosocomial pneumonia.